Health coach offers tips on increasing fiber in your diet to fight disease
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Healthcare Activation Company, Pyx Health, Ranks No. 661 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
With Three-Year Revenue Growth of 631% Percent, This Marks Pyx Health's Fourth Consecutive Appearance on the List NEW YORK, August 12, 2025--(BUSINESS WIRE)--In its annual list of the fastest growing private companies in America, leading media brand Inc. today revealed that Pyx Health has ranked number 661, denoting its fourth consecutive appearance on the Inc. 5000. The prestigious list is a data driven snapshot of the companies experiencing the most success in today's economy, with giants like Microsoft, Meta, Chobani, Under Armour, Timberland, and more previously earning a coveted spot. Founded in 2017, Pyx Health is a member activation company that improves quality outcomes for health plans and their members. Pyx blends personalized technology, real human connection and home-delivered resources to engage members, motivate them, and support taking action to improve their health. Through their offering, Pyx identifies hidden risks, addresses non-medical drivers of health (NMDoH) like transportation to appointments or food insecurity, and helps close gaps in care, ultimately delivering better outcomes for members and reducing healthcare spending. Achieving considerable success since its origins, since late 2023, Pyx Health acquired chronic disease management platform InquisitHealth to supercharge its tech-enablement, and co-founders Cindy and Anne Jordan most recently raised $47.5 million in the lead-up to Pyx's acquisition of food-as-engagement company FarmboxRx. These acquisitions marked a significant milestone for the brand as it continues to expand beyond its roots as a loneliness point solution to fully encircle members with support for the breadth of non-medical barriers to care, like food insecurity – a pervasive and significant need among the CMS populations Pyx Health serves. "Being named in the Inc. 5000 for the fourth consecutive year is a powerful validation of not just our growth, but of our mission to address NMDoH and expand access to care for underserved populations," said Cindy Jordan, CEO and Co-Founder of Pyx Health. "At a time when policy changes threaten to strip vital benefits and access to care from society's most vulnerable populations, our work is more urgent than ever. We're committed to continuing to meet people where they are, with compassion, technology, and a belief that no one should have to navigate their health alone." Pyx's appearance on the list denotes exceptional growth while navigating economic uncertainty, inflationary pressure, and an ever-changing landscape in the healthcare industry. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." Inc. will celebrate the honorees at the 2025 Inc. 5000 Conference & Gala, taking place October 22–24 in Phoenix, and the top 500 will be listed in the Fall issue of Inc. magazine. For the full list, company profiles, and a searchable database by industry and location, visit: To learn more about Pyx Health, please visit: Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit About Pyx Health: Pyx Health is a healthcare activation company on a mission to help health plans engage the members who are hardest to reach, through personalized technology, real human connection and home-delivered resources. Pyx Health's platform is able to identify hidden risks, close gaps in care and address non-medical drivers of health, ultimately helping to overcome barriers to care, and deliver better outcomes for members and stronger impact for health plans. For more information, visit us at and follow us on LinkedIn and Facebook. Because no one gets better alone™. View source version on Contacts Media Contact:Mia HinzSolCommspyxhealth@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
2 minutes ago
- Gizmodo
Experimental ‘Off-the-Shelf' Cancer Vaccine Is Already Prolonging Lives, Study Suggests
An experimental 'off-the-shelf' vaccine for recurring pancreatic and colorectal cancer is showing great promise so far. Early results show that the vaccine appears to be safe and is potentially prolonging people's lives. Researchers at the University of California, Los Angeles, the Memorial Sloan Kettering Cancer Center in New York, and elsewhere are developing the vaccine, called ELI-002. In Phase I trial data released this week, people who received ELI-002 often developed an immune response to a specific type of cancer-linked mutation and lived longer than expected. The team has since launched a larger Phase II trial of the vaccine platform. 'If this result can be confirmed in large randomized clinical trials, this could be utilized in 90% of pancreatic cancers and 50% of colon cancers who have this mutation,' lead study author Zev Wainberg, co-director of the Gastrointestinal Oncology program at UCLA, told Gizmodo. RFK Jr. Yanks $500 Million From Critical mRNA Vaccine Research Cancer vaccines are generally therapeutic, designed to improve our body's natural ability to stop cancer from returning. ELI-002 is a peptide-based vaccine that tries to train our immune system's T cells to go after cells containing a mutated KRAS gene. KRAS mutations often fuel the growth of cancerous cells, and they're commonly found in many solid tumor cancers (up to 25%), particularly pancreatic and colorectal cancers. Unlike vaccines that have to be tuned to a person's specific cancer, ELI-002 is intended to work against a majority of KRAS-containing cancers right from the get-go. In this latest trial, the researchers tested out a version of ELI-002 (ELI-002 2P) on 25 patients: 20 with pancreatic cancer and 5 with colorectal cancer. The patients had undergone standard treatment but continued to have residual cancer cells lingering in their blood, raising the risk of future recurrence. All were given six doses of ELI-002, aimed at their lymph nodes, while half received booster shots as well. About 85% of people generated an immune response to the two mutated KRAS proteins targeted by the vaccine, with two-thirds having a strong response. 67% of people also developed an immune response to other KRAS proteins, suggesting the vaccine further amplified their immunity to these mutations. Overall, people with pancreatic cancer vaccinated with ELI-002 2P survived for 29 months and lived free of cancer recurrence for 15 months on average—better than the average survival and recurrence-free length historically seen with similar cases, according to the researchers. And those with the strongest immune responses fared even better. The team's findings were published Monday in Nature Medicine. Three Years After Experimental Vaccine, These Patients Are Still Cancer-Free Phase I trials aren't intended to conclusively show that an experimental drug or vaccine works, so the findings should still be viewed with some caution until more data is collected. But it certainly looks like we're on the verge of a breakthrough with cancer vaccines. Several candidates have shown similarly encouraging results in human trials, and the first of these newest vaccines could reach the public within the next few years. For their part, Wainberg and his colleagues have already completed enrollment of a Phase II trial for ELI-002, with results expected in 2026. This trial will test an updated version of the vaccine (named ELI-002 7P) that will hopefully cover an even broader array of KRAS mutations.
Yahoo
an hour ago
- Yahoo
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034
The outlook for the gastric cancer treatment market appears favorable, fueled by progress in targeted therapies and immunotherapies. Traditionally, platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer, underscoring the demand for more effective alternatives. New York, USA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight The outlook for the gastric cancer treatment market appears favorable, fueled by progress in targeted therapies and immunotherapies. Traditionally, platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer, underscoring the demand for more effective alternatives. DelveInsight's Gastric Cancer Market Insights report includes a comprehensive understanding of current treatment practices, emerging gastric cancer drugs, market share of individual therapies, and current and forecasted gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Gastric Cancer Market Report According to DelveInsight's analysis, the total gastric cancer market size is expected to grow positively by 2034. The United States accounts for the largest market size of gastric cancer, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. The total number of incident cases of gastric cancer (including GEJ) in the 7MM accounted for approximately 211K in 2024. These cases are expected to increase by 2034. Prominent companies, including Amgen, Jazz Pharmaceuticals, BeiGene, Zymeworks, AstraZeneca, ALX Oncology, Pfizer, KLUS Pharma, Enliven Therapeutics, Ambrx, NovoCodex, and others, are actively working on innovative gastric cancer drugs. Some of the key gastric cancer therapies in the pipeline include Bemarituzumab, ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept (ALX148), TUKYSA (tucatinib), A166 (Trastuzumab botidotin), ELVN-002, ARX788, and others. These novel gastric cancer therapies are anticipated to enter the gastric cancer market in the forecast period and are expected to change the market. Discover which gastric cancer medications are expected to grab the market share @ Gastric Cancer Market Report Gastric Cancer Market Dynamics The gastric cancer market dynamics are anticipated to change in the coming years. HER2-targeted therapies such as HERCEPTIN, ENHERTU, and the anti-PD1 therapy KEYTRUDA offer more precise treatment options that improve efficacy while minimizing side effects compared to traditional chemotherapy. ENHERTU, developed by Daiichi Sankyo and AstraZeneca, is expanding into the first-line (1L) treatment setting, which is expected to boost its patient share and drive market growth. Additionally, there is growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies with immune checkpoint inhibitors (ICIs), presenting a significant opportunity to enhance treatment outcomes and improve patient survival. Overall, the gastric cancer market is poised for expansion, driven by rising incidence rates, an aging population, and continued advancements in treatment approaches, encouraging further investment in research and development. Furthermore, many potential therapies are being investigated for the treatment of gastric cancer, and it is safe to predict that the treatment space will significantly impact the gastric cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the gastric cancer market in the 7MM. However, several factors may impede the growth of the gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a significantly high mortality rate and poor prognosis, driven by low screening rates, a high incidence of refractory or relapsed tumors, and an older patient population; furthermore, the complex tumor biology, including intratumoral heterogeneity, poses challenges for effective treatment and limits current therapies, while the propensity for developing resistance to targeted treatments necessitates ongoing development of next-generation agents, thereby increasing R&D costs. Moreover, gastric cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the gastric cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the gastric cancer market Cancer Treatment Market Gastrectomy is the mainstay of treatment for early-stage gastric or gastroesophageal junction (GEJ) cancers and can potentially cure patients; however, the survival rate for those with advanced resectable disease remains poor despite the advent of perioperative chemotherapy or adjuvant chemoradiation strategies. The choice of treatment depends on several factors, including tumor size, location, and the patient's overall health. In metastatic settings, HER2, a receptor overexpressed or amplified in 6–36% of gastric cancer patients, has emerged as a key therapeutic target. Targeted agents such as HERCEPTIN (trastuzumab), which inhibits HER2-mediated tumor proliferation, and immune checkpoint inhibitors like KEYTRUDA (pembrolizumab), which blocks PD-1/PD-L1 interaction to enhance antitumor immune response, have received FDA approval. More recently, agents like ENHERTU (Daiichi Sankyo) and AIDIXI (Remegen Biosciences) have been approved for second- and third-line treatment, reflecting the growing role of precision therapies in managing advanced gastric cancer. Learn more about the gastric cancer treatment options @ Gastric Cancer Treatment Guidelines Gastric Cancer Emerging Drugs and Companies Pharmaceutical companies developing therapies for treating gastric cancer include Amgen (Bemarituzumab), ALX Oncology (Evorpacept), Jazz Pharmaceuticals, BeiGene, and Zymeworks (ZIIHERA), Enliven Therapeutics (ELVN-002), Ambrx and NovoCodex (ARX788), AstraZeneca (Rilvegostomig and AZD0901), KLUS Pharma (A166), Pfizer (TUKYSA), and others with their candidates in different stages of clinical development. Bemarituzumab is a monoclonal antibody targeting the fibroblast growth factor receptor 2b (FGFR2b) and is under investigation for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. In April 2021, Amgen announced that the U.S. FDA had granted bemarituzumab breakthrough therapy designation. The drug is also undergoing Phase I and Phase II clinical trials in combination with other treatments for these cancers. According to Amgen's May 2025 presentation, the company plans to release data from the Phase III FORTITUDE-101 trial, evaluating bemarituzumab as a first-line treatment for gastric cancer, in Q2 2025. Another Phase III trial, FORTITUDE-102, is expected to report results in the latter half of 2025. ZIIHERA, a bispecific HER2-directed antibody that targets two external HER2 binding sites, received FDA accelerated approval in November 2024 for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), based on an FDA-approved diagnostic. The drug is currently in Phase III development for treating HER2-positive unresectable, locally advanced, or metastatic gastroesophageal adenocarcinoma. Zanidatamab, being jointly developed by Jazz Pharmaceuticals and BeiGene under a license from Zymeworks, the original developer, is also progressing in the gastroesophageal adenocarcinoma (GEA) space. Jazz is exploring zanidatamab's potential use in the neoadjuvant and adjuvant settings for GEA. The pivotal Phase III HERIZON-GEA-01 trial (NCT05152147), evaluating zanidatamab in combination with chemotherapy—with or without tislelizumab—as a first-line therapy for HER2-expressing metastatic GEA, is expected to deliver top-line data in Q2 2025. As per a company presentation from January 2025, Jazz Pharmaceuticals anticipates submitting a supplemental Biologics License Application (sBLA) for zanidatamab later in 2025, aiming for approval in the first-line GEA setting. The anticipated launch of these emerging gastric cancer therapies are poised to transform the gastric cancer market landscape in the coming years. As these cutting-edge gastric cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for gastric cancer, visit @ Gastric Cancer Management Recent Developments in the Gastric Cancer Market In February 2025, AstraZeneca expects the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026. In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer. Gastric Cancer Overview Gastric cancer develops when malignant cells form in the stomach lining. The stomach wall consists of five layers: the mucosa, submucosa, muscularis propria, subserosa, and serosa. The tumour's location and the depth of layer involvement are critical in determining the cancer's stage, which influences both treatment strategies and prognosis. As the cancer progresses from the mucosa to deeper layers, it becomes more advanced, requiring more intensive therapy. To detect gastric cancer, physicians typically assess the patient's medical and family history, conduct a physical examination, and carry out blood and stool tests to check for anemia or internal bleeding. Core diagnostic methods include an upper endoscopy with biopsy, using a thin, illuminated tube to inspect the esophagus, stomach, and duodenum, and barium swallow X-rays for imaging the digestive tract. Further staging is supported by advanced imaging techniques like CT scans, endoscopic ultrasound, PET-CT scans, and MRI, which help shape the treatment plan. The gastric cancer report outlines the disease's underlying biology, diagnostic methods, and a real-life patient case study that traces the journey from initial symptoms to diagnosis and complete treatment. Gastric Cancer Epidemiology Segmentation The gastric cancer epidemiology section provides insights into the historical and current gastric cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The gastric cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Gastric Cancer Stage-specific Cases of Gastric Cancer Gender-specific Cases of Gastric Cancer Biomarker-specific Cases of Gastric Cancer Total Treatable Cases of Gastric Cancer Download the report to understand which factors are driving gastric cancer epidemiology trends @ Gastric Cancer Treatment Algorithm Gastric Cancer Report Metrics Details Study Period 2020–2034 Gastric Cancer Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Gastric Cancer Companies Amgen, Jazz Pharmaceuticals, BeiGene, Zymeworks, AstraZeneca, ALX Oncology, Pfizer, KLUS Pharma, Enliven Therapeutics, Ambrx, NovoCodex, and others Key Gastric Cancer Therapies Bemarituzumab, ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept (ALX148), TUKYSA (tucatinib), A166 (Trastuzumab botidotin), ELVN-002, ARX788, KEYTRUDA, ENHERTU, OPDIVO, CYRAMZA, and others Scope of the Gastric Cancer Market Report Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and emerging therapies Gastric Cancer Market Dynamics: Conjoint Analysis of Emerging Gastric Cancer Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Gastric Cancer Market Access and Reimbursement Discover more about gastric cancer drugs in development @ Gastric Cancer Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Methodology 6 Gastric Cancer: Market Overview at a Glance 6.1 Total Market Share (%) Distribution of Gastric Cancer by Therapies in 2020 6.2 Total Market Share (%) Distribution of Gastric Cancer by Therapies in 2034 7 Disease Background and Overview: Gastric Cancer 7.1 Introduction 7.2 Risk Factors 7.3 Symptoms 7.4 Pathophysiology and disease pathways 7.5 Diagnostic Tests: Biomarker assays 8 Treatment and Guidelines 8.1 Current Treatment Landscape 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale 9.3 Total Incident Cases of Gastric Cancer in the 7MM 9.4 The United States 9.4.1 Total Incident Cases of Gastric Cancer in the United States 9.4.2 Stage-specific Cases of Gastric Cancer in the United States 9.4.3 Gender-specific Cases of Gastric Cancer in the United States 9.4.4 Biomarker-specific Cases of Gastric Cancer in the United States 9.4.5 Total Treatable Cases of Gastric Cancer in the United States 9.5 EU4 and the UK 9.6 Japan 10 Patient Journey 11 Marketed Drugs 11.1 Key Competitors 11.2 ENHERTU (Fam-Trastuzumab Deruxtecan-nxki): AstraZeneca/Daiichi Sankyo 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Development Activities 11.2.4 Clinical Development 11.2.4.1 Clinical Trial Information 11.2.5 Safety and Efficacy 11.2.6 Analyst Views 11.3 OPDIVO (nivolumab): Bristol-Myers Squibb List to be continued in the report… 12 Emerging Therapies 12.1 Key Competitors 12.2 Bemarituzumab: Amgen 12.2.1 Product Description 12.2.2 Other Developmental Activities 12.2.3 Clinical Development 12.2.3.1 Clinical Trial Information 12.2.4 Safety and Efficacy 12.2.5 Analyst Views 12.3 ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks List to be continued in the report… 13 Gastric Cancer: Market Size 13.1 Key Findings 13.2 Market Outlook 13.3 Conjoint Analysis 13.4 Key Market Forecast Assumptions 13.4.1 Cost Assumptions and Rebates 13.4.2 Pricing Trends 13.4.3 Analogue Assessment 13.4.4 Launch Year and Therapy Uptakes 13.5 Total Market Size of Gastric Cancer in the 7MM 13.6 The United States 13.6.1 Total Market Size of Gastric Cancer in the United States 13.6.2 Total Market Size of Gastric Cancer by Therapies in the United States 13.7 EU4 and the UK 13.7.1 Total Market Size of Gastric Cancer in EU4 and the UK 13.7.2 Total Market Size of Gastric Cancer by Therapies in EU4 and the UK 13.8 Japan 13.8.1 Total Market Size of Gastric Cancer in Japan 13.8.2 Total Market Size of Gastric Cancer by Therapies in Japan 14 Unmet Needs 15 SWOT Analysis 16 KOL Views 17 Market Access and Reimbursement 18 Bibliography 19 Report Methodology Related Reports Gastric Cancer Pipeline Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, among others. HER2+ Gastric Cancer Market HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HER2+ gastric cancer companies including AstraZeneca, Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, among others. HER2+ Gastric Cancer Pipeline HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others. Metastatic Prostate Cancer Market Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. HER2+ Gastric Cancer Epidemiology HER2+ Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends. Gastric Cancer Epidemiology Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the gastric cancer epidemiology trends. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
